Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
12.10
+2.09 (20.88%)
At close: Jun 2, 2025, 4:00 PM
12.39
+0.29 (2.40%)
After-hours: Jun 2, 2025, 7:35 PM EDT

Maze Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22
Net Income
51.9452.23-100.42-114.94
Depreciation & Amortization
3.033.34.093.82
Loss (Gain) From Sale of Investments
---2.4
Loss (Gain) on Equity Investments
---3.54
Stock-Based Compensation
10.569.658.756.74
Other Operating Activities
7.5412.37.072.48
Change in Accounts Payable
0.62-0.20.4-3.78
Change in Other Net Operating Assets
-3.82-1.32-6.720.54
Operating Cash Flow
69.8875.95-86.83-99.2
Capital Expenditures
-1.17-1.15-0.44-1.97
Investment in Securities
----1.2
Investing Cash Flow
-1.17-1.15-0.44-3.17
Long-Term Debt Issued
-24.4816.18-
Net Debt Issued (Repaid)
0.2624.4816.18-
Issuance of Common Stock
128.250.730.210.15
Other Financing Activities
-3.65-3.15--
Financing Cash Flow
195.6492.8516.391.73
Net Cash Flow
264.35167.65-70.88-100.65
Free Cash Flow
68.7174.81-87.27-101.17
Free Cash Flow Margin
41.02%44.66%--
Free Cash Flow Per Share
7.3827.40-38.14-50.33
Cash Income Tax Paid
1.231.23--
Levered Free Cash Flow
-52.09-52.55-
Unlevered Free Cash Flow
-52.09-52.55-
Change in Net Working Capital
--4.313.35-
Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q